Oncoinvent ASA

Share Issue/Capital Change • Nov 25, 2025

Oncoinvent ASA: Last day of trading in subscription rights

Oncoinvent ASA: Last day of trading in subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

25 November 2025: Reference is made to the stock exchange announcements

published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,

and subsequent announcements, regarding the contemplated fully underwritten

rights issue of 260,000,000 new shares in the Company (the "Offer Shares")

raising gross proceeds of NOK 130 million (the "Rights Issue").

The period for trading in the subscription rights in the Rights Issue (the

"Subscription Rights") with ticker "ONCIT" will expire today, on 25 November

2025 at 16:30 hours (CET).

The subscription period for the Rights Issue (the "Subscription Period") expires

at 16:30 hours (CET) on 1 December 2025.

Subscription Rights that are not sold before close of trading today, on 25

November 2025 at 16:30 hours (CET) or not used to subscribe for Offer Shares

before the expiry of the Subscription Period will have no value and will lapse

without compensation to the holder.

Subscriptions for Offer Shares must be made within the expiry of the

Subscription Period and may either be made through the VPS online subscription

system or by submitting a correctly completed subscription form to ABG Sundal

Collier AS or DNB Carnegie, a part of DNB Bank ASA (acting as managers for the

Rights Issue, the "Managers").

For more information, and the complete terms and conditions of the Rights Issue,

please refer to the prospectus dated 28 October 2025 prepared by the Company and

approved by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet)

(the "Prospectus"). Subject to applicable local securities law, the Prospectus,

including the subscription form for the Rights Issue, is available at

https://www.abgsc.com/transactions and https://www.dnb.no/emisjoner.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email:(soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting

micro-metastases in the peritoneum post-surgery, harnessing the benefits of

modern radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical

development program in two indications. One Phase 1 trial and one Phase 1/2a

trial have been completed and one randomized Phase 2 trial in ovarian cancer is

currently ongoing in the US and Europe. Early clinical efficacy data are highly

encouraging, and no serious toxicity or safety concerns have been reported to

date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug

products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo

Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly

target microscopic metastases in the abdominal cavity following surgery.

Radspherin® is currently in development as a post-surgical treatment for

patients with cancer that has spread to the abdominal cavity - a group with very

limited treatment options today. The drug candidate offers a distinctly unique

therapeutic approach with several differentiating features, including the use of

radium-224, single-dose treatment with a sustained therapeutic effect, non

-systemic administration, direct targeting and an exceptional dose-to-tumor

ratio, maximizing efficacy while limiting harm to healthy tissue

IMPORTANT INFORMATION

This announcement does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities of the Company in the United

States or any other jurisdiction. Copies of this document may not be sent to

jurisdictions, or distributed in or sent from jurisdictions, in which this is

barred or prohibited by law. The securities of the Company may not be offered or

sold in the United States absent registration or an exemption from registration

under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act").

The securities of the Company have not been, and will not be, registered under

the U.S. Securities Act. Any sale in the United States of the securities

mentioned in this communication will be made solely to "qualified institutional

buyers" as defined in Rule 144A under the U.S. Securities Act. No public

offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made by

means of the Prospectus prepared by the Company in connection the Rights Issue,

as approved by the The Financial Supervisory Authority of Norway (Nw.

Finanstilsynet) on 28 October 2025. This announcement is an advertisement and is

not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European

Parliament and of the Council of 14 June 2017 on prospectuses to be published

when securities are offered to the public or admitted to trading on a regulated

market, and repealing Directive 2003/71/EC (as amended) as implemented in any

EEA Member State (the "Prospectus Regulation"). Investors should not subscribe

for any securities referred to in this announcement except on the basis of

information contained in the Prospectus. Copies of the Prospectus is available

from the Company's registered office and, subject to certain exceptions, on the

website of the Managers.

In any EEA Member State, this communication is only addressed to and is only

directed at qualified investors in that Member State within the meaning of the

Prospectus Regulation, i.e., only to investors who can receive the offer without

an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only

directed at Qualified Investors who (i) are investment professionals falling

within Article 19(5) of the Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling

within Article 49(2)(a) to (d) of the Order (high net worth companies,

unincorporated associations, etc.) (all such persons together being referred to

as "Relevant Persons"). These materials are directed only at Relevant Persons

and must not be acted on or relied on by persons who are not Relevant Persons.

Any investment or investment activity to which this announcement relates is

available only to Relevant Persons and will be engaged in only with Relevant

Persons. Persons distributing this communication must satisfy themselves that it

is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,

Australia, Canada, Japan, the United States or any other jurisdiction in which

such release, publication or distribution would be unlawful, and it does not

constitute an offer or invitation to subscribe for or purchase any securities in

such countries or in any other jurisdiction. In particular, the document and the

information contained herein should not be distributed or otherwise transmitted

into the United States or to publications with a general circulation in the

United States of America.

The Managers are acting for the Company in connection with the Rights Issue and

no one else and will not be responsible to anyone other than the Company for

providing the protections afforded to their respective clients or for providing

advice in relation to the Rights Issue or any transaction or arrangement

referred to in this announcement. Matters discussed in this announcement may

constitute forward-looking statements. Forward-looking statements are statements

that are not historical facts and may be identified by words such as

"anticipate", "believe", "continue", "estimate", "expect", "intends", "may",

"should", "will" and similar expressions. The forward-looking statements in this

release are based upon various assumptions, many of which are based, in turn,

upon further assumptions.

Although the Company believes that these assumptions were reasonable when made,

these assumptions are inherently subject to significant known and unknown risks,

uncertainties, contingencies and other important factors which are difficult or

impossible to predict and are beyond its control. Such risks, uncertainties,

contingencies and other important factors could cause actual events to differ

materially from the expectations expressed or implied in this release by such

forward-looking statements. The information, opinions and forward-looking

statements contained in this announcement speak only as at its date and are

subject to change without notice. This announcement is made by and is the

responsibility of, the Company. Neither the Managers nor any of their affiliates

makes any representation as to the accuracy or completeness of this announcement

and none of them accepts any responsibility for the contents of this

announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon

in substitution for the exercise of independent judgment. It is not intended as

investment advice and under no circumstances is it to be used or considered as

an offer to sell, or a solicitation of an offer to buy any securities or a

recommendation to buy or sell any securities of the Company. No reliance may be

placed for any purpose on the information contained in this announcement or its

accuracy, fairness or completeness. Neither the Managers nor any of their

respective affiliates accepts any liability arising from the use of this

announcement.